Stem Cells Spin S.A (SCS) fair value: what the stock is really worth
As of Oct 22, 2026: fair value (intrinsic value) of Stem Cells Spin S.A stock PLN 0.34, price PLN 0.44, upside -22.7%, quality 48 out of 100. Rating: overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Fair value above price?No
Good quality?No
Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with oneYes, for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 14, 2026.
How to read this chart
60‑month range 0.1410 PLN – 2.00 PLN · fair‑value band 0.2500 PLN – 0.4300 PLN · the 0.4400 PLN price screens above the 0.3400 PLN fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 14, 2026.
Follow Stem Cells Spin in your weekly email
Every Wednesday you see whether Stem Cells Spin is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Stem Cells Spin S.A. operates as a biotechnology company in Poland. It engages in the development, cultivation, and usage of stem cells using MIC-1 stem cells for human and veterinary medicine, and dermocosmetics applications. The company offers biodermocosmetics under the Revitacell brand name.
Show moreShow less
The company was founded in 2009 and is based in Wroclaw, Poland. Stem Cells Spin S.A. operates as a subsidiary of Medcervin Sp. Z O.O.
Stock analysis
Stem Cells Spin S.A (SCS) currently trades at 0.4400 PLN, while our model-based Fair Value estimate is 0.3400 PLN, 22.7% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 2 models at a data quality of 96/100, which puts the data coverage at low.
Scenario range: 0.2500 PLN (bear) to 0.4300 PLN (bull), the price of 0.4400 PLN sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 48/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Stem Cells Spin S.A reported revenue of 65.7K PLN in FY2025 versus 526K PLN in FY2021, a compound −40.5%/yr. Reported net income was −518K PLN in FY2025.
Our AI-assisted moat analysis scores the competitive advantage at 6 out of 100 (low confidence).
What moves the price
The share trades about 19% below its 52-week high and 47% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 2% fair-value upside, at −23%, SCS screens richer than that median.
Fair Value models
Bear0.2500 PLNFair Value 0.3400 PLNBull0.4300 PLN
Price 0.4400 PLN · Upside -22.7%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.6/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+21.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−35.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−24.5%
Start year 2020 (pandemic). Over 10 years: −21.2% a year
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−21.2%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
15.5% (2020) → −787.1% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 594 stocks
Beats the industry median on 4/7 measures
A mixed picture versus its industry peers.
Valuation
Quality Score48 · Above median
Fair Value upside−22.7% · Above median
Profitability
Return on assets−5.4% · Above median
Growth and dividend
Revenue growth (quarter YoY)−26.8% · Bottom 25%
Balance sheet
Debt / equity0.01× · Below median
Valuation Multiplesvs Biotechnology median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Stem Cells Spin S.A (SCS) overvalued or undervalued?
As of Oct 14, 2026, our model estimates a fair value of 0.3400 PLN versus a price of 0.4400 PLN, about −23% upside (overvalued).
What is the fair value of SCS?
Our model-based fair value for Stem Cells Spin S.A is 0.3400 PLN (as of Oct 14, 2026), built from audited fundamentals. The current price: 0.4400 PLN.
What is the quality score of SCS?
Stem Cells Spin S.A has a Quality Score of 48/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Stem Cells Spin S.A (SCS)?
Our model-based price target is the fair value of 0.3400 PLN (as of Oct 14, 2026) from 2 valuation models. Cautious scenario 0.2500 PLN, optimistic scenario 0.4300 PLN. It is a calculation from audited fundamentals, not an analyst target.
What is the Stem Cells Spin S.A stock forecast for 2026?
Our models put fair value at 0.3400 PLN, about −23% upside versus a price of 0.4400 PLN (overvalued). Cautious scenario 0.2500 PLN, optimistic scenario 0.4300 PLN. The calculation is refreshed regularly with new filings.
What is the revenue of Stem Cells Spin S.A (SCS)?
Stem Cells Spin S.A reported trailing-twelve-month revenue of about 58.5K PLN (latest available figure, as of Oct 14, 2026).
What is the intrinsic value of Stem Cells Spin S.A (SCS)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Stem Cells Spin S.A it is 0.3400 PLN per share (as of Oct 14, 2026), against a price of 0.4400 PLN. It is the blended result of 2 valuation models (cash flow, earnings, asset, dividend).
Is Stem Cells Spin S.A stock overvalued or undervalued in 2026?
As of Oct 14, 2026, SCS trades above its calculated fair value: price 0.4400 PLN, fair value 0.3400 PLN, a gap of about −23% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SCS?
No. The price is what the market pays today (0.4400 PLN); the fair value is what the company's own numbers justify (0.3400 PLN). For Stem Cells Spin S.A the two are 0.1000 PLN per share apart. That gap is exactly why we show both numbers side by side.
How much is Stem Cells Spin S.A worth?
The market values Stem Cells Spin S.A at about 18.2M PLN (market capitalisation, as of Oct 14, 2026). Per share that is 0.4400 PLN; our models calculate a fair value of 0.3400 PLN per share.
What do the bullish and bearish scenarios say about SCS?
Our models span a range for Stem Cells Spin S.A: cautious scenario 0.2500 PLN, base 0.3400 PLN, optimistic 0.4300 PLN per share (as of Oct 14, 2026, price 0.4400 PLN). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Stem Cells Spin S.A (SCS)?
Balance-sheet figures for Stem Cells Spin S.A (as of Oct 14, 2026): return on equity −9.3%, debt of 0.01 per unit of equity. They feed the Quality Score of 48/100, which measures business quality independently of the share price.
How far is SCS from its 52-week high?
Stem Cells Spin S.A trades at 0.4400 PLN, about 19% below its 52-week high of 0.5400 PLN and 47% above the low of 0.3000 PLN (as of Oct 22, 2026). Distance from the high says nothing about value: that is what the fair value of 0.3400 PLN is for.
Which stocks are comparable to Stem Cells Spin S.A?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Stem Cells Spin S.A stock attractive at the current price?
The data as of Oct 14, 2026: price 0.4400 PLN, calculated fair value 0.3400 PLN (−23%), Quality Score 48/100, from 2 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of SCS calculated?
We run Stem Cells Spin S.A through 2 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 0.3400 PLN, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 12.3 % above its aggregate fair value. Stem Cells Spin S.A itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Stem Cells Spin S.A (SCS)?
The closing price on Oct 22, 2026 was 0.4400 PLN. Our model-based fair value is 0.3400 PLN, about −23% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Stem Cells Spin S.A right now?
The price sits above even our optimistic bull case (0.4300 PLN). The favourable scenario is already priced in. Solid but not exceptional quality (48/100) and above fair value, neither a clear bargain nor a standout compounder. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Stem Cells Spin S.A
How large is the market capitalisation of Stem Cells Spin S.A (SCS)?
The market capitalisation of Stem Cells Spin S.A is 18.2M PLN (≈ $4.6M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Stem Cells Spin S.A (SCS)?
Earnings per share at Stem Cells Spin S.A are −0.0100 PLN. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Stem Cells Spin S.A (SCS)?
The return on equity (ROE) of Stem Cells Spin S.A is −9.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Stem Cells Spin S.A (SCS)?
On an EBIT basis the return on assets of Stem Cells Spin S.A is −2.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Stem Cells Spin S.A (SCS)?
The operating margin of Stem Cells Spin S.A is −844% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Stem Cells Spin S.A (SCS)?
Revenue at Stem Cells Spin S.A is growing −26.8% versus a year earlier (3y avg −35.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Stem Cells Spin S.A (SCS) generate?
The free cash flow of Stem Cells Spin S.A is −85.9K PLN (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Stem Cells Spin S.A (SCS) carry?
The net debt of Stem Cells Spin S.A is 84.9K PLN (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Stem Cells Spin S.A in the live analysis
One click puts Stem Cells Spin S.A on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.
Thin data
Oct 14, 2026